Stanadyne 10-Q 13 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013
Entity Information [Line Items]	'
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	'2013
Document Fiscal Period Focus	'Q3
Trading Symbol	'CK0001323274
Entity Registrant Name	'Stanadyne Holdings, Inc.
Entity Central Index Key	'0001323274
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Non-accelerated Filer
Entity Common Stock, Shares Outstanding	105,652,581
Stanadyne Corporation [Member]	'
Entity Information [Line Items]	'
Entity Registrant Name	'STANADYNE CORP
Entity Central Index Key	'0001053439
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Non-accelerated Filer
Entity Common Stock, Shares Outstanding	1,000

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$1,983	$2,907
Accounts receivable, net of allowance for uncollectible accounts of $291 and $258 as of September 30, 2013 and December 31, 2012, respectively	47,216	32,688
Inventories, net	43,131	40,203
Prepaid expenses and other assets	4,955	3,366
Deferred income taxes	130	128
Total current assets	97,415	79,292
Property, plant and equipment, net	79,153	79,391
Goodwill	136,705	136,705
Intangible and other assets, net	64,257	67,211
Total assets	377,530	362,599
Current liabilities:	'	'
Accounts payable	33,261	24,134
Accrued liabilities	16,806	23,331
Current maturities of long-term debt	218,367	32,416
Current portion of capital lease obligations	577	1,043
Current deferred income tax liability	677	879
Total current liabilities	269,688	81,803
Long-term debt, excluding current maturities	110,377	265,268
Deferred income taxes	19,588	19,530
Capital lease obligations, excluding current portion	2,563	2,963
Other non-current liabilities	53,835	56,252
Total liabilities	456,051	425,816
Commitments and Contingencies (Note 11)	'	'
Redeemable non-controlling interest	537	939
Stanadyne stockholder's equity:	'	'
Common stock	1,065	1,065
Additional paid-in capital	52,325	52,693
Accumulated other comprehensive loss	-28,829	-29,462
Accumulated deficit	-102,968	-87,801
Treasury stock, at cost, 890,000 shares as of September 30, 2013 and December 31, 2012	-651	-651
Total stockholders' deficit	-79,058	-64,156
Total liabilities and stockholder's equity	377,530	362,599
Stanadyne Corporation [Member]	'	'
Current assets:	'	'
Cash and cash equivalents	1,982	2,906
Accounts receivable, net of allowance for uncollectible accounts of $291 and $258 as of September 30, 2013 and December 31, 2012, respectively	47,216	32,688
Inventories, net	43,131	40,203
Prepaid expenses and other assets	4,955	3,366
Deferred income taxes	130	669
Total current assets	97,414	79,832
Property, plant and equipment, net	79,153	79,391
Goodwill	136,705	136,705
Intangible and other assets, net	63,900	66,659
Total assets	377,172	362,587
Current liabilities:	'	'
Accounts payable	33,261	24,134
Accrued liabilities	15,090	18,723
Current maturities of long-term debt	218,367	32,416
Current portion of capital lease obligations	577	1,043
Current deferred income tax liability	249	0
Total current liabilities	267,544	76,316
Long-term debt, excluding current maturities	4,377	165,268
Deferred income taxes	20,018	9,779
Capital lease obligations, excluding current portion	2,563	2,963
Due to Stanadyne Holdings, Inc.	2,376	3,234
Other non-current liabilities	53,835	56,252
Total liabilities	350,713	313,812
Commitments and Contingencies (Note 11)	'	'
Redeemable non-controlling interest	537	939
Stanadyne stockholder's equity:	'	'
Common stock	'	'
Additional paid-in capital	69,117	74,823
Accumulated other comprehensive loss	-20,679	-21,312
Accumulated deficit	-22,516	-5,675
Total stockholders' deficit	25,922	47,836
Total liabilities and stockholder's equity	$377,172	$362,587

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Allowance for uncollectible accounts	$291	$258
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	106,542,581	106,542,581
Common stock, shares outstanding	105,652,581	105,652,581
Treasury stock, shares	890,000	890,000
Stanadyne Corporation [Member]	'	'
Allowance for uncollectible accounts	$291	$258
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	10,000	10,000
Common stock, shares issued	1,000	1,000
Common stock, shares outstanding	1,000	1,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net sales	$71,892	$58,141	$190,914	$195,086
Cost of goods sold	54,717	42,012	148,370	141,423
Gross profit	17,175	16,129	42,544	53,663
Selling, general and administrative expenses	11,473	11,216	29,072	33,409
Amortization of intangible assets	704	704	2,112	2,112
Management fees	0	188	0	563
Operating income	4,998	4,021	11,360	17,579
Interest income	-4	-1	-10	-5
Interest expense	9,249	8,084	26,850	24,368
Other (income) expense	-131	-36	-161	690
(Loss) income from operations before income tax expense (benefit)	-4,116	-4,026	-15,319	-7,474
Income tax expense	-1,587	-362	435	-3
Net (loss) income	-2,529	-3,664	-15,754	-7,471
Less: net loss (income) attributable to non-controlling interest	207	-351	587	-920
Net (loss) income attributable to the stockholders	-2,322	-4,015	-15,167	-8,391
Stanadyne Corporation [Member]	'	'	'	'
Net sales	71,892	58,141	190,914	195,086
Cost of goods sold	54,717	42,012	148,370	141,423
Gross profit	17,175	16,129	42,544	53,663
Selling, general and administrative expenses	11,403	11,101	28,863	33,207
Amortization of intangible assets	704	704	2,112	2,112
Management fees	0	188	0	563
Operating income	5,068	4,136	11,569	17,781
Interest income	-4	-1	-10	-5
Interest expense	6,089	5,020	17,560	15,173
Other (income) expense	-131	-36	-161	690
(Loss) income from operations before income tax expense (benefit)	-886	-847	-5,820	1,923
Income tax expense	13,513	-672	11,608	525
Net (loss) income	-14,399	-175	-17,428	1,398
Less: net loss (income) attributable to non-controlling interest	207	-351	587	-920
Net (loss) income attributable to the stockholders	($14,192)	($526)	($16,841)	$478

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net (loss) income	($2,529)	($3,664)	($15,754)	($7,471)
Other comprehensive income (loss), before tax:	'	'	'	'
Foreign currency translation adjustments	494	177	633	-393
Comprehensive (loss) income	-2,035	-3,487	-15,121	-7,864
Net Income (Loss) Attributable to Noncontrolling Interest	-207	351	-587	920
Less: comprehensive (loss) income attributable to the non-controlling interest	207	-351	587	-920
Comprehensive income (loss) attributable to the stockholders	-1,828	-3,838	-14,534	-8,784
Stanadyne Corporation [Member]	'	'	'	'
Net (loss) income	-14,399	-175	-17,428	1,398
Other comprehensive income (loss), before tax:	'	'	'	'
Foreign currency translation adjustments	494	177	633	-393
Comprehensive (loss) income	-13,905	2	-16,795	1,005
Net Income (Loss) Attributable to Noncontrolling Interest	-207	351	-587	920
Less: comprehensive (loss) income attributable to the non-controlling interest	207	-351	587	-920
Comprehensive income (loss) attributable to the stockholders	($13,698)	($349)	($16,208)	$85

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net (loss) income	($15,754)	($7,471)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation and amortization	13,074	9,424
Amortization of debt discount and deferred financing fees	2,338	1,487
Deferred income taxes	-157	-56
(Gain) loss on disposal of property, plant and equipment	-223	70
Changes in operating assets and liabilities	-20,885	-15,006
Net cash (used in) provided by operating activities	-21,607	-11,552
Cash flows from investing activities:	'	'
Capital expenditures	-11,765	-10,190
Decrease in restricted cash	0	165
Proceeds from disposal of property, plant and equipment	492	0
Net cash used in investing activities	-11,273	-10,025
Cash flows from financing activities:	'	'
Proceeds from U.S. revolver	73,565	71,115
Payments on U.S. revolver	-72,515	-50,675
Proceeds from foreign overdraft facilities	3,556	3,707
Payments on foreign overdraft facilities	-2,498	-4,149
Proceeds from U.S. term loans	31,000	0
Proceeds from foreign term loans	1,264	1,713
Payments on foreign term loans	-1,375	-887
Payments on capital lease obligations	-757	-395
Payments of debt issuance costs	-1,584	0
Net cash provided by financing activities	30,656	20,429
Cash and cash equivalents:	'	'
Net decrease in cash and cash equivalents	-2,224	-1,148
Effect of exchange rate changes on cash	1,300	730
Cash and cash equivalents at beginning of period	2,907	1,771
Cash and cash equivalents at end of period	1,983	1,353
Stanadyne Corporation [Member]	'	'
Cash flows from operating activities:	'	'
Net (loss) income	-17,428	1,398
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation and amortization	13,074	9,424
Amortization of debt discount and deferred financing fees	2,143	1,292
Deferred income taxes	11,017	524
(Gain) loss on disposal of property, plant and equipment	-223	70
Changes in operating assets and liabilities	-18,851	-12,260
Net cash (used in) provided by operating activities	-10,268	448
Cash flows from investing activities:	'	'
Capital expenditures	-11,765	-10,190
Decrease in restricted cash	0	165
Proceeds from disposal of property, plant and equipment	492	0
Net cash used in investing activities	-11,273	-10,025
Cash flows from financing activities:	'	'
Proceeds from U.S. revolver	73,565	71,115
Payments on U.S. revolver	-72,515	-50,675
Proceeds from foreign overdraft facilities	3,556	3,707
Payments on foreign overdraft facilities	-2,498	-4,149
Proceeds from U.S. term loans	25,000	0
Proceeds from foreign term loans	1,264	1,713
Payments on foreign term loans	-1,375	-887
Dividends paid	-5,338	-12,000
Payments on capital lease obligations	-757	-395
Payments of debt issuance costs	-1,584	0
Net cash provided by financing activities	19,318	8,429
Cash and cash equivalents:	'	'
Net decrease in cash and cash equivalents	-2,223	-1,148
Effect of exchange rate changes on cash	1,299	730
Cash and cash equivalents at beginning of period	2,906	1,770
Cash and cash equivalents at end of period	$1,982	$1,352

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) (USD $)	Total	Stanadyne Corporation [Member]	Common Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
In Thousands, except Share data				Stanadyne Corporation [Member]		Stanadyne Corporation [Member]		Stanadyne Corporation [Member]		Stanadyne Corporation [Member]
Beginning balance at Dec. 31, 2011	($47,319)	$61,824	$1,065	'	$51,525	$85,653	($24,365)	($18,045)	($74,893)	($5,784)	($651)
Beginning balance shares at Dec. 31, 2011	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Dividend paid	'	-6,000	'	'	'	-6,000	'	'	'	'	'
Adjustment of the redeemable non-controlling interest to redemption value	411	411	'	'	411	411	'	'	'	'	'
Net income (loss)	-1,544	871	'	'	'	'	'	'	-1,544	871	'
Foreign currency translation adjustment	-217	-217	'	'	'	'	-217	-217	'	'	'
Ending balance at Mar. 31, 2012	-48,669	56,889	1,065	'	51,936	80,064	-24,582	-18,262	-76,437	-4,913	-651
Ending balance shares at Mar. 31, 2012	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Beginning balance at Dec. 31, 2011	-47,319	61,824	1,065	'	'	'	'	'	'	'	-651
Beginning balance shares at Dec. 31, 2011	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Net income (loss)	-8,391	478	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustments	-393	-393	'	'	'	'	'	'	'	'	'
Ending balance at Sep. 30, 2012	-55,139	50,873	1,065	'	'	'	'	'	'	'	-651
Ending balance shares at Sep. 30, 2012	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Beginning balance at Mar. 31, 2012	-48,669	56,889	1,065	'	51,936	80,064	-24,582	-18,262	-76,437	-4,913	-651
Beginning balance shares at Mar. 31, 2012	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Adjustment of the redeemable non-controlling interest to redemption value	215	215	'	'	215	215	'	'	'	'	'
Net income (loss)	-2,832	133	'	'	'	'	'	'	-2,832	133	'
Foreign currency translation adjustment	-353	-353	'	'	'	'	-353	-353	'	'	'
Ending balance at Jun. 30, 2012	-51,639	56,884	1,065	'	52,151	80,279	-24,935	-18,615	-79,269	-4,780	-651
Ending balance shares at Jun. 30, 2012	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Dividend paid	'	-6,000	'	'	'	-6,000	'	'	'	'	'
Adjustment of the redeemable non-controlling interest to redemption value	338	338	'	'	338	338	'	'	'	'	'
Net income (loss)	-4,015	-526	'	'	'	'	'	'	-4,015	-526	'
Foreign currency translation adjustments	177	177	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustment	177	177	'	'	'	'	177	177	'	'	'
Ending balance at Sep. 30, 2012	-55,139	50,873	1,065	'	52,489	74,617	-24,758	-18,438	-83,284	-5,306	-651
Ending balance shares at Sep. 30, 2012	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Beginning balance at Dec. 31, 2012	-64,156	47,836	1,065	'	52,693	74,823	-29,462	-21,312	-87,801	-5,675	-651
Beginning balance shares at Dec. 31, 2012	106,542,581	1,000	106,542,581	1,000	'	'	'	'	'	'	890,000
Dividend paid	'	-5,338	'	'	'	-5,338	'	'	'	'	'
Adjustment of the redeemable non-controlling interest to redemption value	-261	-261	'	'	-261	-261	'	'	'	'	'
Net income (loss)	-9,742	-2,852	'	'	'	'	'	'	-9,742	-2,852	'
Foreign currency translation adjustment	67	67	'	'	'	'	67	67	'	'	'
Ending balance at Mar. 31, 2013	-74,092	39,452	1,065	'	52,432	69,224	-29,395	-21,245	-97,543	-8,527	-651
Ending balance shares at Mar. 31, 2013	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Beginning balance at Dec. 31, 2012	-64,156	47,836	1,065	'	'	'	'	'	'	'	-651
Beginning balance shares at Dec. 31, 2012	106,542,581	1,000	106,542,581	1,000	'	'	'	'	'	'	890,000
Net income (loss)	-15,167	-16,841	'	'	'	'	'	'	'	'	'
Foreign currency translation adjustments	633	633	'	'	'	'	'	'	'	'	'
Ending balance at Sep. 30, 2013	-79,058	25,922	1,065	'	'	'	'	'	'	'	-651
Ending balance shares at Sep. 30, 2013	106,542,581	1,000	106,542,581	1,000	'	'	'	'	'	'	890,000
Beginning balance at Mar. 31, 2013	-74,092	39,452	1,065	'	52,432	69,224	-29,395	-21,245	-97,543	-8,527	-651
Beginning balance shares at Mar. 31, 2013	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Adjustment of the redeemable non-controlling interest to redemption value	-209	-209	'	'	-209	-209	'	'	'	'	'
Net income (loss)	-3,103	203	'	'	'	'	'	'	-3,103	203	'
Foreign currency translation adjustment	72	72	'	'	'	'	72	72	'	'	'
Ending balance at Jun. 30, 2013	-77,332	39,518	1,065	'	52,223	69,015	-29,323	-21,173	-100,646	-8,324	-651
Ending balance shares at Jun. 30, 2013	'	'	106,542,581	1,000	'	'	'	'	'	'	890,000
Adjustment of the redeemable non-controlling interest to redemption value	102	102	'	'	102	102	'	'	'	'	'
Net income (loss)	-2,322	-14,192	'	'	'	'	'	'	-2,322	-14,192	'
Foreign currency translation adjustments	494	494	'	'	'	'	'	494	'	'	'
Foreign currency translation adjustment	494	494	'	'	'	'	494	'	'	'	'
Ending balance at Sep. 30, 2013	($79,058)	$25,922	$1,065	'	$52,325	$69,117	($28,829)	($20,679)	($102,968)	($22,516)	($651)
Ending balance shares at Sep. 30, 2013	106,542,581	1,000	106,542,581	1,000	'	'	'	'	'	'	890,000

Business_Organization_and_Sign

Business, Organization and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Business, Organization and Significant Accounting Policies	'
	Business, Organization and Significant Accounting Policies
	Description of Business. Stanadyne Holdings, Inc. (“Holdings”) owns all of the outstanding common stock of Stanadyne Intermediate Holding Corp. (“SIHC”). SIHC owns all of the outstanding common stock of Stanadyne Corporation (together with its consolidated subsidiaries, “Stanadyne”). A majority of the outstanding common stock of Holdings is owned by funds managed by Kohlberg Management IV, L.L.C. (“Kohlberg”). Collectively, Holdings, SIHC and Stanadyne hereinafter are referred to as the “Company.” Holdings and Stanadyne are separate reporting companies.
	Holdings is a holding company with no operations beyond those of its indirectly, wholly-owned subsidiary, Stanadyne. Stanadyne is a leading designer and manufacturer of highly engineered, precision manufactured engine components, including fuel injection equipment primarily for diesel engines and, more recently for high pressure gasoline engines. Stanadyne sells engine components to original equipment manufacturers (“OEMs”) in a variety of applications, including agricultural and construction vehicles and equipment, industrial products, automobiles, light duty trucks and marine equipment. The aftermarket is a core element of Stanadyne’s operations. The Company sells replacement parts and units through various global channels to service its products, including the service organizations of its OEM customers, its own authorized network of distributors and dealers, and major aftermarket distribution companies.
	Liquidity and Financial Position. The Company’s financial position, results of operations and cash flows have been adversely affected by our manufacturing reorganization in 2011 as well as the global recession in 2012, and may continue to be affected by significant volatility in the worldwide capital, credit and commodities markets, lower corporate profits and increased capital spending, and concerns about inflation. Holdings incurred consolidated net losses and negative cash flows from operations in each of the last three years and the nine months ended September 30, 2013. Stanadyne incurred a net loss and negative cash flows from operations in 2011 and the nine months ended September 30, 2013. Holdings and Stanadyne are both highly leveraged with total debt of $328.7 million and $222.7 million, respectively, outstanding at September 30, 2013. The indenture governing Stanadyne’s Senior Subordinated Notes limits the amount of dividends that can be paid to an amount calculated under a Restricted Payments Basket (as defined by the terms of the indenture) (“RP Basket”). Holdings relies on dividends from SIHC which are received from Stanadyne to make semi-annual interest payments on its Senior Discount Notes. Failure to make these interest payments would result in an event of default under the terms of the Senior Discount Notes. Beginning in 2012, Kohlberg advised Holdings that it would provide financial assistance to Holdings, to the extent necessary, in meeting the semi-annual interest payments. On August 14, 2013, Holdings entered into a Convertible Subordinated Note ("Notes") agreement totaling $6.0 million with Kohlberg. The proceeds from the Notes were received by Holdings on August 14, 2013 and were used to meet Holdings' August 15, 2013 interest payment obligation on Holdings' Senior Discount Notes. If necessary, Kohlberg will provide Holdings with additional equity of up to $6.0 million to meet the semi-annual interest payment that will come due on February 15, 2014. Please refer to Note 4, Long-term Debt and Financing Arrangements, for further details.
	The Company estimates that cash flows from operations combined with existing cash balances and amounts available under the U.S. Revolver and limited financial assistance from Kohlberg, if necessary, will be sufficient to fund its cash requirements for planned capital investments, interest payments on outstanding indebtedness, and projected working capital needs for the next twelve months. The U.S Revolver is scheduled to mature on April 30, 2014 and we are actively engaged in activities that would include the renewal or replacement of this expiring credit facility. In the event the Company’s efforts are unsuccessful, we may need to incur more indebtedness, restructure existing indebtedness, raise additional equity capital, or a combination of these items, which may have a further negative impact on our business, results of operations, and cash flows.
	The Company does not anticipate that existing sources of cash will be sufficient to repay debt scheduled to mature beginning on April 30, 2014 and, accordingly, intends to refinance such amounts prior to maturity in order to maintain sufficient resources for its operations. The Company can provide no assurance that it will be able to complete this refinancing or that financing options available will be on favorable or acceptable terms. If the Company were unable to refinance or replace the maturing debt obligations, it would be in default under the terms of agreements governing that indebtedness, which would result in cross-defaults under its other outstanding indebtedness and would allow the lenders to both Holdings and Stanadyne to exercise their rights and remedies as defined under their respective agreements, including their right to accelerate the repayment of existing indebtedness. Such an acceleration would have a material adverse effect on the financial position, results of operations and cash flows for both Holdings and Stanadyne.
	Principles of Consolidation. The condensed consolidated financial statements of Holdings include the accounts of Holdings and all of Holdings’ direct and indirect wholly-owned subsidiaries: SIHC, Stanadyne, Stanadyne, SpA (“SpA”), and Stanadyne Changshu Corporation (“SCC”). The condensed consolidated financial statements of Stanadyne include the accounts of Stanadyne and Stanadyne’s wholly-owned subsidiaries: SpA and SCC. A joint venture, Stanadyne Amalgamations Private Limited (“SAPL”), is fully consolidated with Holdings and Stanadyne based on Stanadyne’s controlling share, while the remaining share is recorded as a non-controlling interest. Intercompany balances have been eliminated in consolidation.
	Basis of Presentation. The condensed consolidated financial statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary for a fair statement for the periods presented. The Company’s quarterly results are subject to fluctuation and consequently the results of operations and cash flows for any quarter are not necessarily indicative of the results and cash flows for any future period. For further information, refer to the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. These notes to condensed consolidated financial statements apply to both Holdings and Stanadyne unless otherwise noted.
	Income Tax Accounting. For the three and nine months ended September 30, 2013, the Company applied an estimated annual effective tax rate to interim period pre-tax income (loss) to calculate the income tax expense (benefit) as the effective tax rate method provided a reliable estimate for computing income taxes in interim periods. In addition to the effective annual tax rate applied to the nine months ended September 30, 2013, Stanadyne provided an additional discrete tax benefit for the impact of 2012 research and development credits resulting from the American Taxpayer Relief Act of 2012 enacted retroactively and signed into law on January 3, 2013. For the three and nine months ended September 30, 2012, the Company computed its provision for income taxes based on the actual tax rate by applying the discrete method, as the Company determined that small changes in estimated income or loss would result in significant changes under the estimated annual effective tax rate method. Therefore, applying an estimate of the annual effective tax rate to the 2012 periods would not provide a reliable estimate for interim reporting periods.
	Income tax expense for Stanadyne in the third quarter of 2013 totaled $13.5 million and (1,525.2)% of pre-tax loss versus an income tax benefit of $0.7 million and 79.3% of pre-tax loss in the third quarter of 2012. The effective income tax rates differed from the amount computed by applying the U.S. statutory rate of 35% to pre-tax (loss) income in the third quarter of 2013 and 2012. The difference in 2013 resulted primarily from the establishment of a valuation allowance against deferred tax assets in the U.S. as it was determined that it is more likely than not that deferred tax assets would not be realized based on recent losses incurred by Stanadyne. The difference in 2012 resulted primarily from the profitability in the foreign jurisdictions where the related tax impact was offset by corresponding changes in the foreign valuation allowances.
	As of December 31, 2012, the Company had a valuation allowance of $3.9 million against deferred tax assets in India, China and Italy. It is possible that some or all of the existing valuation allowance may decrease within the next 12 months, primarily dependent on the Company's ability to demonstrate that it can generate sufficient income prior to the expiration of those deferred tax assets. Decreases in existing valuation allowances would have a material impact on the Company's annual effective tax rate. Although the Company's ability to demonstrate that it can generate sufficient income prior to the expiration of those deferred tax assets is not assured, management believes that during the next 12 months some or all of these deferred tax assets may be realized.
	Income tax benefit for Holdings in the third quarter of 2013 totaled $1.6 million and 38.6% of pre-tax loss versus an income tax benefit of $0.4 million and 9.0% of pre-tax loss in the third quarter of 2012. The effective income tax rates differed from the amount computed by applying the U.S. statutory rate of 35% to the pre-tax loss in the third quarter of 2013 and 2012. The difference in 2013 and 2012 resulted primarily from changes to the valuation allowances as well as non-deductible interest expense.
	Reclassifications. Certain prior year amounts have been reclassified to conform to the current year's presentation.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Components of inventories are as follows:
		As of		As of
		September 30,		December 31,
		2013		2012
	Raw materials	$	21,753	$	18,048
	Work in process	11,755		12,035
	Finished goods	9,623		10,120
		$	43,131	$	40,203

Intangible_and_Other_Assets

Intangible and Other Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible and Other Assets	'
	Intangible and Other Assets
	Major components of intangible and other assets are listed below:
		Holdings
		As of				As of
		30-Sep-13				31-Dec-12
		Gross  Carrying		Accumulated		Gross  Carrying		Accumulated
		Value		Amortization		Value		Amortization
	Trademarks / trade names	$	51,100	$	—	$	51,100	$	—
	Technology / patents	24,300		17,118		24,300		16,150
	Customer contracts	15,252		13,960		15,252		12,816
	Debt issuance costs	16,240		13,333		14,660		10,995
	Other	1,851		75		1,935		75
		$	108,743	$	44,486	$	107,247	$	40,036
		Stanadyne
		As of				As of
		30-Sep-13				31-Dec-12
		Gross  Carrying		Accumulated		Gross  Carrying		Accumulated
		Value		Amortization		Value		Amortization
	Trademarks / trade names	$	51,100	$	—	$	51,100	$	—
	Technology / patents	24,300		17,118		24,300		16,150
	Customer contracts	15,252		13,960		15,252		12,816
	Debt issuance costs	13,885		11,335		12,305		9,192
	Other	1,851		75		1,935		75
		$	106,388	$	42,488	$	104,892	$	38,233
	Amortization expense of intangible assets for the Company, exclusive of the amortization of debt issuance costs, was $704 for the three months ended September 30, 2013 and 2012 and $2,112 for the nine months ended September 30, 2013 and 2012. Estimated annual amortization expense for the Company’s intangible assets is expected to be $2,816 in 2013, $2,202 in 2014, $1,093 in 2015, $1,072 in 2016, $1,072 in 2017 and $1,072 in 2018.
	Amortization of debt discount and debt issuance costs is included as interest expense in the accompanying condensed consolidated statements of operations for Holdings of $844 and $505 for the three months ended September 30, 2013 and 2012, respectively, and $2,338 and $1,487 for the nine months ended September 30, 2013 and 2012, respectively. Amortization of debt issuance costs is included as interest expense in the accompanying condensed consolidated statements of operations for Stanadyne of $779 and $440 for the three months ended September 30, 2013 and 2012, respectively, and $2,143 and $1,292 for the nine months ended September 30, 2013 and 2012, respectively.

Longterm_Debt_and_Financing_Ar

Long-term Debt and Financing Arrangements	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Long-term Debt and Financing Arrangements	'
	Long-term Debt and Financing Arrangements
	Long-term debt consisted of:
		Holdings				Stanadyne
		September 30,		December 31,		September 30,		December 31,
		2013		2012		2013		2012
	U.S. Revolver	$	22,140	$	21,090	$	22,140	$	21,090
	U.S. term debt, payable to Jefferies Finance LLC on June 30, 2014, bearing interest at a rate of 10.0%	25,000		—		25,000		—
	U.S. Convertible Subordinated Notes, payable on August 14, 2018, bearing interest at a rate of 12.0%	6,000		—		0		—
	Senior Subordinated Notes, payable on August 15, 2014, bearing interest at a rate of 10.0%	160,000		160,000		160,000		160,000
	Holdings Senior Discount Notes, payable on February 15, 2015, bearing interest at a rate of 12.0%	100,000		100,000		—		—
	SAPL term debt, payable to Indian banks through 2017, bearing interest at rates ranging from 11.0% to 12.0%	4,934		5,982		4,934		5,982
	SAPL Debentures	1,057		1,251		1,057		1,251
	SAPL debt, payable to Indian banks through 2013, bearing interest at rates ranging from 11.0% to 12.75%	4,874		4,660		4,874		4,660
	SCC debt, payable to Shanghai-Pudong Development Bank through 2013, bearing interest at rates ranging from 6.9% to 7.2%	2,214		2,608		2,214		2,608
	SpA debt, payable to Italian banks through 2013, bearing interest at rates ranging from 4.0% to 6.1%	2,525		2,093		2,525		2,093
	Total long-term debt	328,744		297,684		222,744		197,684
	Less current maturities of long-term debt	218,367		32,416		218,367		32,416
	Long-term debt, excluding current maturities	$	110,377	$	265,268	$	4,377	$	165,268
	The fair values of the Senior Subordinated Notes and Holdings’ Senior Discount Notes are based on bid prices and are classified within Level 1 of the valuation hierarchy. The fair value of the Senior Subordinated Notes at September 30, 2013 and December 31, 2012 was $152.0 and $148.8 million, respectively. The fair value of Holdings’ Senior Discount Notes at September 30, 2013 and December 31, 2012 was $55.0 and $68.0 million, respectively. The fair values of the Company’s other borrowings approximated their recorded values at September 30, 2013 and December 31, 2012 based on similar borrowing agreements offered by other major institutional banks and are classified within Level 2 of the valuation hierarchy.
	On February 13, 2013, Stanadyne and Jefferies Finance LLC (“Jefferies”) entered into a Second-Lien Term Loan Agreement (the “Term Loan Agreement”) providing for a term loan in an aggregate original principal amount of $25.0 million (with potential incremental term loans up to an additional $15.0 million in aggregate).  The term loan is guaranteed by Stanadyne's immediate parent, SIHC and is secured by a second-lien position in certain tangible and intangible assets of Stanadyne, including property, plant and equipment, fixed assets, copyrights, trademarks and patents.  Covenants include restrictions on pre-payments, restrictions on dividends, and limitations on sales of assets and sale and leaseback transactions.  The term loan bears interest at 10.0% per annum and matures on June 30, 2014.  Interest only is payable quarterly.  Prepayment may be required upon sales of assets or a change of control. Stanadyne took these actions in order to enhance its available liquidity during the production launch of new high pressure gasoline and diesel fuel pump products.
	On August 13, 2009, Stanadyne (as borrower) and SIHC (as guarantor) entered into a revolving credit agreement (the “U.S. Revolver”) with Wells Fargo Capital Finance, LLC (“Wells Fargo”). The U.S. Revolver, as amended through 2012, provided for maximum borrowings of $55.8 million based on availability, as defined, and is secured by all Stanadyne and SIHC assets, as well as a pledge of 65% of Stanadyne’s stock in SpA, SAPL, and SCC. The U.S. Revolver is comprised of a domestic inventory and accounts receivable facility, a domestic fixed asset facility, a foreign accounts receivable sub-facility guaranteed by the Export-Import Bank of the United States and a guaranteed facility, as defined by the credit agreement. The terms of the agreement also allow the Company to permanently reduce the amount of available credit under the Guaranteed Facility, in increments of $1.0 million, with a 10 day notice, in the event equity infusions are made to Holdings at the direction of Kohlberg. Interest on borrowings under the U.S. Revolver is at a Base Rate (as defined by the agreement) or LIBOR, plus an applicable margin ranging between 1.25% and 1.75% through 2012, depending on the level of excess availability. All borrowings under the U.S. Revolver are due and payable on April 30, 2014. The U.S. Revolver is subject to a fixed charge coverage ratio covenant of 1.1 if availability is less than $4.0 million, and certain other affirmative and negative covenants common to an asset-backed loan agreement. The U.S. Revolver also limits the amount of dividends and other payments that can be made by Stanadyne to SIHC. Further, the Company is required to provide annual audited financial statements to the bank within 105 days of year end.
	On February 13, 2013, Stanadyne and Wells Fargo entered into a Fifth Amendment to Credit Agreement (the “Fifth Credit Amendment”) and a Fifth Amendment to EXIM Guarantied Credit Agreement (the “Fifth EXIM Amendment”).  The Fifth Credit Amendment increased the maximum revolver amount by $5.0 million, increasing the total commitment to $60.8 million. The Fifth Credit Amendment also increased interest rates by 0.25% based on levels of Availability (as defined by the Credit Agreement), and modified certain clauses within the inventory sub-facility to add an inventory block and within the accounts receivable sub-facility to increase the revolving line limit and to modify customer concentration limits. In connection with this amendment, Stanadyne also entered into a Fifth EXIM Amendment to incorporate the modifications added by the Fifth Credit Amendment into the EXIM Guarantied Credit Agreement. All other terms of the EXIM Guarantied Credit Agreement were materially unchanged from the prior agreements.
	On August 12, 2013, Stanadyne and Wells Fargo entered into a Sixth Amendment to EXIM Guarantied Credit Agreement (the “Sixth EXIM Amendment”). The Sixth EXIM Amendment updated the maturity date of the agreement to the earlier of April 30, 2014 or the termination date of the Domestic Commitments, as defined, to coincide with the terms of the U.S. Revolver. All other terms of the credit agreements were materially unchanged from the prior agreements.
	On August 14, 2013, Holdings and Kohlberg entered into a Convertible Subordinated Note ("Notes") agreement providing for a term loan in an aggregate principal amount of $6.0 million. The Notes carry a 5-year term with an interest rate of 12.0% per annum payable in semi-annual installments in arrears commencing in February 2014. At the option of the Company, the interest payments may be made utilizing payment-in-kind notes. The Notes include mandatory prepayment provisions upon change of control or refinancing of Holdings' Senior Discount Notes. The Notes are subordinated to the Senior Discount Notes and are convertible to common stock at fair market value. The guaranteed facility portion of the U.S. Revolver, as defined by the credit agreement, was reduced by $6.0 million as a result of this additional debt, decreasing the total commitment under the Credit Agreement to $55.8 million.
	As of September 30, 2013, the U.S. Revolver had Availability, as defined, of $25.4 million, after reflecting $22.1 million of borrowings and $3.2 million used for standby letters of credit, as well as other limitations related to inventory and accounts receivable.

Pension_Plans_and_Other_Postre

Pension Plans and Other Postretirement Health Care and Life Insurance Plans	9 Months Ended
	Sep. 30, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension Plans and Other Postretirement Health Care and Life Insurance Plans	'
	Pension Plans and Other Postretirement Health Care and Life Insurance Plans
	The Company has a noncontributory defined benefit pension plan for eligible domestic employees and also has two nonqualified plans, which are designed to supplement the benefits payable to designated employees. The components of the net periodic pension cost for the periods shown are as follows:
		Three months ended September 30,						Nine months ended September 30,
		2013			2012			2013			2012
	Interest cost	$	1,288		$	1,405		$	3,864		$	4,215
	Expected return on plan assets	(1,798		)	(1,601		)	(5,396		)	(4,803		)
	Recognized net actuarial loss	923			775			2,770			2,326
	Net periodic pension cost	$	413		$	579		$	1,238		$	1,738
	The Company funds the pension plan in an amount at least equal to the minimum required contribution as determined by the plan’s actuaries, but not in excess of the maximum tax-deductible amount under Section 404 of the Internal Revenue Code. The Company may make discretionary contributions of any amount within this range based on financial circumstances and strategic considerations, which typically vary from year to year.
	The Company contributed $1.5 million and $3.2 million to the pension plan during the three and nine months ended September 30, 2013, respectively. The Company expects the minimum required contributions to the pension plan to total approximately $4.1 million in 2013. The Company contributed $2.2 million and $4.9 million to the pension plan during the three and nine months ended September 30, 2012 and $5.0 million for the full year of 2012.
	Postretirement Health Care and Life Insurance
	The Company’s U.S. subsidiaries make available certain health care and life insurance benefits for eligible retired employees. The components of the net periodic income for the periods shown were as follows:
		Three months ended September 30,						Nine months ended September 30,
		2013			2012			2013			2012
	Service cost	$	8		$	7		$	23		$	22
	Interest cost	20			26			60			78
	Recognized net actuarial gain	(174		)	(186		)	(521		)	(559		)
	Net periodic postretirement income	$	(146	)	$	(153	)	$	(438	)	$	(459	)

Property_Plant_and_Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property, Plant and Equipment
	During the first quarter of 2013, the Company consolidated its operations on the Windsor, Connecticut campus from three buildings to two buildings in an effort to reduce costs and better utilize the available space. The book value of the vacated building was depreciated down to its net realizable value, resulting in an additional $2.9 million of accelerated depreciation recognized during the three months ended March 31, 2013.

Equity_Compensation_Plan

Equity Compensation Plan	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Equity Compensation Plan	'
	Equity Compensation Plan
	In 2004, Holdings established the 2004 Equity Incentive Plan (the "Option Plan") to provide for the award of non-qualified stock options to attract and retain people who are in a position to make a significant contribution to the success of the Company and its subsidiaries. Awards granted under the Option Plan vest over a period of one to four years contingent upon achievement of certain financial performance targets as defined by the Option Plan and expire 10 years after the date of grant.
	The Company uses a Black-Scholes option-pricing model to calculate the fair value of options. The key assumptions for this valuation method include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, exercise price, fair market value of common stock, probability that financial targets will be met, and forfeiture rate. Many of these assumptions are judgmental and highly sensitive in the determination of compensation expense.
	The following table summarizes information about the Option Plan and other option grants for the three months ended September 30, 2013:
		Three months ended September 30, 2013
		Outstanding				Exercisable
		Stock Options		Weighted Average Exercise Price *		Stock Options	Weighted Average Exercise Price *
	30-Jun-13	14,778,750		$	0.49	3,008,750	$	0.47
	Exercised	—		—		—	—
	Cancelled	(3,375,000	)	0.47		—	—
	Granted	875,000		0.47		—	—
	30-Sep-13	12,278,750		$	0.49	3,008,750	$	0.47
	The following tables summarizes information about the Option Plan and other option grants for the nine months ended September 30, 2013:
		Nine months ended September 30, 2013
		Outstanding				Exercisable
		Stock Options		Weighted Average Exercise Price *		Stock Options	Weighted Average Exercise Price *
	31-Dec-12	14,778,750		$	0.49	3,008,750	$	0.47
	Exercised	—		—		—	—
	Cancelled	(3,375,000	)	0.47		—	—
	Granted	875,000		0.47		—	—
	30-Sep-13	12,278,750		$	0.49	3,008,750	$	0.47
	* Represents per share price.
	During the three and nine months ended September 30, 2013, in connection with the retirement of our former President and CEO, M. David Jones, previously issued unvested options to purchase 3,375,000 shares were cancelled in accordance with the Option Plan. In addition, the Company extended the expiration date of Mr. Jones' vested options to purchase 875,000 shares through March 30, 2016 and granted to Mr. Jones stock options to purchase 875,000 shares of Holdings common stock in substitution of a portion of previously issued unvested options, which terminated upon his retirement. These new stock options were issued outside of the Company's Option Plan, were fully vested at grant, and are exercisable only upon a change of control. Their exercise price of $0.47 per share is the same as the exercise price of his previous options.
	For the three and nine months ended September 30, 2013 and 2012, no compensation expense was recognized as management determined that it is not probable that the performance targets associated with the stock option awards will be achieved.

Redeemable_Noncontrolling_Inte

Redeemable Non-controlling Interest and Financial Instruments	9 Months Ended
	Sep. 30, 2013
Noncontrolling Interest [Abstract]	'
Redeemable Non-controlling Interest and Financial Instruments	'
	Redeemable Non-controlling Interest and Financial Instruments
	The expansion of manufacturing operations in SAPL in 2010 was funded through a combination of new debt and equity issuances. The process included entering into a put arrangement with the existing non-controlling interest partners as part of an amendment to the SAPL Joint Venture Agreement with respect to the common securities that represent the 35.1% non-controlling interest. The non-controlling interest partners have an option to put their ownership interests to Stanadyne during a 90-day period beginning March 1, 2015. Due to the put option, the non-controlling interest is redeemable and does not qualify as permanent equity. As a result, redeemable non-controlling interest is recorded in the mezzanine section of the condensed consolidated balance sheets and is reported at estimated redemption value. At September 30, 2013 and December 31, 2012, the redemption value was $0.5 million and $0.9 million, respectively. Changes in the redemption value are charged to retained earnings if available or to additional paid-in capital.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	Fair value, as defined in accounting guidance, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In addition, fair value should be the exit price, or price received to sell the asset or liability as opposed to the entry price, or price paid to acquire an asset or assume a liability.
	The following table below shows how the Company categorized certain financial assets and liabilities based on the types of inputs used in valuation techniques for measuring fair value:
		Fair Value Measurements at
		30-Sep-13
		Quoted Prices in		Significant		Significant		Total
		Active Markets		Other		Unobservable
		for Identical		Observable		Inputs (Level 3)
		Assets (Level 1)		Inputs (Level 2)
	Financial liabilities:
	SAPL debenture embedded conversion option	$	—	$	—	$	1,012	$	1,012
		Fair Value Measurements at
		31-Dec-12
		Quoted Prices in		Significant		Significant		Total
		Active Markets		Other		Unobservable
		for Identical		Observable		Inputs (Level 3)
		Assets (Level 1)		Inputs (Level 2)
	Financial liabilities:
	SAPL debenture embedded conversion option	$	—	$	—	$	1,150	$	1,150
	The conversion option embedded in the SAPL debenture is considered a derivative and is recorded at its fair value. The value of the option is calculated using a Monte Carlo simulation approach, which takes into account certain assumptions which include the value of SAPL equity, a discount yield of 15.75%, volatility of 30% and risk free rate of 7.93%, among others. Increases or decreases in any of the input assumptions would not result in a material change to the fair value measurement of the SAPL debenture embedded conversion option.
	Unrealized losses (gains), which are included in other income in the condensed consolidated statement of operations, of $28 and $(36) were the only activities for Level 3 liabilities for the three months ended September 30, 2013 and 2012, respectively. For the nine months ended September 30, 2013 and 2012, unrealized (gains) losses totaled $(2) and $690, respectively.

Segments

Segments	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segments	'
	Segments
	The Company has one reportable segment. The Company manufactures its own proprietary products including fuel pumps for diesel and gasoline engines, injectors and filtration systems for diesel engines, and various non-proprietary products manufactured under contract for other companies. The Company’s proprietary products currently account for the majority of its sales.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	The Company is involved in various legal and regulatory proceedings generally incidental to its business. While the results of any litigation or regulatory issue contain an element of uncertainty, management believes that the outcome of any known, pending or threatened legal proceeding, or all of them combined, will not have a material adverse effect on the Company’s consolidated financial statements.
	The Company is subject to potential environmental liabilities as a result of various claims and legal actions, which are pending or may be asserted against the Company. Reserves for such liabilities have been established, and no insurance recoveries have been anticipated in the determination of the reserves. In management’s opinion, the aforementioned claims will be resolved without material adverse effect on the consolidated results of operations, financial position or cash flows of the Company. In conjunction with the acquisition of SIHC from Metromedia Company (“Metromedia”) on December 11, 1997, Metromedia agreed to partially indemnify Stanadyne for certain environmental matters. The effect of this indemnification is to limit the Company’s financial exposure for known environmental issues.
	The Company estimates and records the warranty liability associated with its manufactured products at the time they are sold. The changes in the Company’s warranty liability are provided below:
		Three months ended September 30,						Nine months ended September 30,
		2013			2012			2013			2012
	Warranty liability, beginning of period	$	1,272		$	726		$	893		$	774
	Warranty expense based on products sold	202			234			1,038			611
	Warranty claims paid	(322		)	(270		)	(779		)	(695		)
	Warranty liability, end of period	$	1,152		$	690		$	1,152		$	690
	The Company’s warranty accrual is included as a component of accrued liabilities on the condensed consolidated balance sheets.

Recently_Issued_Accounting_Sta

Recently Issued Accounting Standards	9 Months Ended
	Sep. 30, 2013
Accounting Changes and Error Corrections [Abstract]	'
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	Comprehensive Income. In February 2013, the FASB issued ASU No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” This ASU intends to improve the reporting of reclassifications out of accumulated other comprehensive income by requiring entities to provide information about the reclassified amounts by component. The guidance is effective prospectively for reporting periods beginning after December 15, 2012. This ASU does not have a material impact on our financial statements or disclosures.

Business_Organization_and_Sign1

Business, Organization and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Changes and Error Corrections [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation. The condensed consolidated financial statements of Holdings include the accounts of Holdings and all of Holdings’ direct and indirect wholly-owned subsidiaries: SIHC, Stanadyne, Stanadyne, SpA (“SpA”), and Stanadyne Changshu Corporation (“SCC”). The condensed consolidated financial statements of Stanadyne include the accounts of Stanadyne and Stanadyne’s wholly-owned subsidiaries: SpA and SCC. A joint venture, Stanadyne Amalgamations Private Limited (“SAPL”), is fully consolidated with Holdings and Stanadyne based on Stanadyne’s controlling share, while the remaining share is recorded as a non-controlling interest. Intercompany balances have been eliminated in consolidation.
Income Tax Accounting	'
	Income Tax Accounting. For the three and nine months ended September 30, 2013, the Company applied an estimated annual effective tax rate to interim period pre-tax income (loss) to calculate the income tax expense (benefit) as the effective tax rate method provided a reliable estimate for computing income taxes in interim periods. In addition to the effective annual tax rate applied to the nine months ended September 30, 2013, Stanadyne provided an additional discrete tax benefit for the impact of 2012 research and development credits resulting from the American Taxpayer Relief Act of 2012 enacted retroactively and signed into law on January 3, 2013. For the three and nine months ended September 30, 2012, the Company computed its provision for income taxes based on the actual tax rate by applying the discrete method, as the Company determined that small changes in estimated income or loss would result in significant changes under the estimated annual effective tax rate method. Therefore, applying an estimate of the annual effective tax rate to the 2012 periods would not provide a reliable estimate for interim reporting periods.
	Income tax expense for Stanadyne in the third quarter of 2013 totaled $13.5 million and (1,525.2)% of pre-tax loss versus an income tax benefit of $0.7 million and 79.3% of pre-tax loss in the third quarter of 2012. The effective income tax rates differed from the amount computed by applying the U.S. statutory rate of 35% to pre-tax (loss) income in the third quarter of 2013 and 2012. The difference in 2013 resulted primarily from the establishment of a valuation allowance against deferred tax assets in the U.S. as it was determined that it is more likely than not that deferred tax assets would not be realized based on recent losses incurred by Stanadyne. The difference in 2012 resulted primarily from the profitability in the foreign jurisdictions where the related tax impact was offset by corresponding changes in the foreign valuation allowances.
	As of December 31, 2012, the Company had a valuation allowance of $3.9 million against deferred tax assets in India, China and Italy. It is possible that some or all of the existing valuation allowance may decrease within the next 12 months, primarily dependent on the Company's ability to demonstrate that it can generate sufficient income prior to the expiration of those deferred tax assets. Decreases in existing valuation allowances would have a material impact on the Company's annual effective tax rate. Although the Company's ability to demonstrate that it can generate sufficient income prior to the expiration of those deferred tax assets is not assured, management believes that during the next 12 months some or all of these deferred tax assets may be realized.
	Income tax benefit for Holdings in the third quarter of 2013 totaled $1.6 million and 38.6% of pre-tax loss versus an income tax benefit of $0.4 million and 9.0% of pre-tax loss in the third quarter of 2012. The effective income tax rates differed from the amount computed by applying the U.S. statutory rate of 35% to the pre-tax loss in the third quarter of 2013 and 2012. The difference in 2013 and 2012 resulted primarily from changes to the valuation allowances as well as non-deductible interest expense.
Comprehensive Income	'
	Comprehensive Income. In February 2013, the FASB issued ASU No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” This ASU intends to improve the reporting of reclassifications out of accumulated other comprehensive income by requiring entities to provide information about the reclassified amounts by component. The guidance is effective prospectively for reporting periods beginning after December 15, 2012. This ASU does not have a material impact on our financial statements or disclosures.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Components of Inventories	'
	Components of inventories are as follows:
		As of		As of
		September 30,		December 31,
		2013		2012
	Raw materials	$	21,753	$	18,048
	Work in process	11,755		12,035
	Finished goods	9,623		10,120
		$	43,131	$	40,203

Intangible_and_Other_Assets_Ta

Intangible and Other Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Major Components of Intangible and Other Assets	'
	Major components of intangible and other assets are listed below:
		Holdings
		As of				As of
		30-Sep-13				31-Dec-12
		Gross  Carrying		Accumulated		Gross  Carrying		Accumulated
		Value		Amortization		Value		Amortization
	Trademarks / trade names	$	51,100	$	—	$	51,100	$	—
	Technology / patents	24,300		17,118		24,300		16,150
	Customer contracts	15,252		13,960		15,252		12,816
	Debt issuance costs	16,240		13,333		14,660		10,995
	Other	1,851		75		1,935		75
		$	108,743	$	44,486	$	107,247	$	40,036
		Stanadyne
		As of				As of
		30-Sep-13				31-Dec-12
		Gross  Carrying		Accumulated		Gross  Carrying		Accumulated
		Value		Amortization		Value		Amortization
	Trademarks / trade names	$	51,100	$	—	$	51,100	$	—
	Technology / patents	24,300		17,118		24,300		16,150
	Customer contracts	15,252		13,960		15,252		12,816
	Debt issuance costs	13,885		11,335		12,305		9,192
	Other	1,851		75		1,935		75
		$	106,388	$	42,488	$	104,892	$	38,233

Longterm_Debt_and_Financing_Ar1

Long-term Debt and Financing Arrangements (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt	'
	Long-term debt consisted of:
		Holdings				Stanadyne
		September 30,		December 31,		September 30,		December 31,
		2013		2012		2013		2012
	U.S. Revolver	$	22,140	$	21,090	$	22,140	$	21,090
	U.S. term debt, payable to Jefferies Finance LLC on June 30, 2014, bearing interest at a rate of 10.0%	25,000		—		25,000		—
	U.S. Convertible Subordinated Notes, payable on August 14, 2018, bearing interest at a rate of 12.0%	6,000		—		0		—
	Senior Subordinated Notes, payable on August 15, 2014, bearing interest at a rate of 10.0%	160,000		160,000		160,000		160,000
	Holdings Senior Discount Notes, payable on February 15, 2015, bearing interest at a rate of 12.0%	100,000		100,000		—		—
	SAPL term debt, payable to Indian banks through 2017, bearing interest at rates ranging from 11.0% to 12.0%	4,934		5,982		4,934		5,982
	SAPL Debentures	1,057		1,251		1,057		1,251
	SAPL debt, payable to Indian banks through 2013, bearing interest at rates ranging from 11.0% to 12.75%	4,874		4,660		4,874		4,660
	SCC debt, payable to Shanghai-Pudong Development Bank through 2013, bearing interest at rates ranging from 6.9% to 7.2%	2,214		2,608		2,214		2,608
	SpA debt, payable to Italian banks through 2013, bearing interest at rates ranging from 4.0% to 6.1%	2,525		2,093		2,525		2,093
	Total long-term debt	328,744		297,684		222,744		197,684
	Less current maturities of long-term debt	218,367		32,416		218,367		32,416
	Long-term debt, excluding current maturities	$	110,377	$	265,268	$	4,377	$	165,268

Pension_Plans_and_Other_Postre1

Pension Plans and Other Postretirement Health Care and Life Insurance Plans (Tables)	9 Months Ended
	Sep. 30, 2013
Pension plans defined benefit [Member]	'
Components of Net Periodic Pension Expense (Benefit)	'
	The components of the net periodic pension cost for the periods shown are as follows:
		Three months ended September 30,						Nine months ended September 30,
		2013			2012			2013			2012
	Interest cost	$	1,288		$	1,405		$	3,864		$	4,215
	Expected return on plan assets	(1,798		)	(1,601		)	(5,396		)	(4,803		)
	Recognized net actuarial loss	923			775			2,770			2,326
	Net periodic pension cost	$	413		$	579		$	1,238		$	1,738
Postretirement health care and life insurance [Member]	'
Components of Net Periodic Pension Expense (Benefit)	'
	The components of the net periodic income for the periods shown were as follows:
		Three months ended September 30,						Nine months ended September 30,
		2013			2012			2013			2012
	Service cost	$	8		$	7		$	23		$	22
	Interest cost	20			26			60			78
	Recognized net actuarial gain	(174		)	(186		)	(521		)	(559		)
	Net periodic postretirement income	$	(146	)	$	(153	)	$	(438	)	$	(459	)

Equity_Compensation_Plan_Table

Equity Compensation Plan (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity	'
	The following table summarizes information about the Option Plan and other option grants for the three months ended September 30, 2013:
		Three months ended September 30, 2013
		Outstanding				Exercisable
		Stock Options		Weighted Average Exercise Price *		Stock Options	Weighted Average Exercise Price *
	30-Jun-13	14,778,750		$	0.49	3,008,750	$	0.47
	Exercised	—		—		—	—
	Cancelled	(3,375,000	)	0.47		—	—
	Granted	875,000		0.47		—	—
	30-Sep-13	12,278,750		$	0.49	3,008,750	$	0.47
	The following tables summarizes information about the Option Plan and other option grants for the nine months ended September 30, 2013:
		Nine months ended September 30, 2013
		Outstanding				Exercisable
		Stock Options		Weighted Average Exercise Price *		Stock Options	Weighted Average Exercise Price *
	31-Dec-12	14,778,750		$	0.49	3,008,750	$	0.47
	Exercised	—		—		—	—
	Cancelled	(3,375,000	)	0.47		—	—
	Granted	875,000		0.47		—	—
	30-Sep-13	12,278,750		$	0.49	3,008,750	$	0.47
	* Represents per share price.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Categorizes of Financial Assets and Liabilities Based on Types of Inputs Used in Valuation Techniques for Measuring Fair Value	'
	The following table below shows how the Company categorized certain financial assets and liabilities based on the types of inputs used in valuation techniques for measuring fair value:
		Fair Value Measurements at
		30-Sep-13
		Quoted Prices in		Significant		Significant		Total
		Active Markets		Other		Unobservable
		for Identical		Observable		Inputs (Level 3)
		Assets (Level 1)		Inputs (Level 2)
	Financial liabilities:
	SAPL debenture embedded conversion option	$	—	$	—	$	1,012	$	1,012
		Fair Value Measurements at
		31-Dec-12
		Quoted Prices in		Significant		Significant		Total
		Active Markets		Other		Unobservable
		for Identical		Observable		Inputs (Level 3)
		Assets (Level 1)		Inputs (Level 2)
	Financial liabilities:
	SAPL debenture embedded conversion option	$	—	$	—	$	1,150	$	1,150

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Changes in Warranty Liability	'
	The changes in the Company’s warranty liability are provided below:
		Three months ended September 30,						Nine months ended September 30,
		2013			2012			2013			2012
	Warranty liability, beginning of period	$	1,272		$	726		$	893		$	774
	Warranty expense based on products sold	202			234			1,038			611
	Warranty claims paid	(322		)	(270		)	(779		)	(695		)
	Warranty liability, end of period	$	1,152		$	690		$	1,152		$	690

Business_Organization_and_Sign2

Business, Organization and Significant Accounting Policies - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Aug. 14, 2013

Maximum [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Impact of Revision on Holdings [Member]

Impact of Revision on Stanadyne [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Convertible Subordinated Debt [Member]

Convertible Subordinated Debt [Member]

Description Of Business [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Holdings incurred net losses

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt

$328,744,000

'

$328,744,000

'

$297,684,000

'

$222,744,000

'

$222,744,000

'

$197,684,000

$328,700,000

$222,700,000

$55,800,000

'

Aggregate original principal amount of term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

Additional equity

'

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

'

Semi-annual interest payments

'

'

15-Feb-14

'

'

'

'

'

'

'

'

'

'

'

'

Valuation allowance

'

'

'

'

3,900,000

'

'

'

'

'

'

'

'

'

'

Income tax (benefit) expense

($1,587,000)

($362,000)

$435,000

($3,000)

'

'

$13,513,000

($672,000)

$11,608,000

$525,000

'

'

'

'

'

Pre-tax income (loss) tax rate

38.60%

9.00%

'

'

'

'

-1525.20%

79.30%

'

'

'

'

'

'

'

Income tax rate differential

35.00%

35.00%

'

'

'

'

35.00%

35.00%

'

'

'

'

'

'

'

Inventories_Components_of_Inve

Inventories - Components of Inventories (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$21,753	$18,048
Work in process	11,755	12,035
Finished goods	9,623	10,120
Inventories, net	$43,131	$40,203

Intangible_and_Other_Assets_Ma

Intangible and Other Assets - Major Components of Intangible and Other Assets (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	$108,743	$107,247
Accumulated Amortization	44,486	40,036
Stanadyne Corporation [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	106,388	104,892
Accumulated Amortization	42,488	38,233
Trademarks/trade names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	51,100	51,100
Accumulated Amortization	'	'
Trademarks/trade names [Member] | Stanadyne Corporation [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	51,100	51,100
Accumulated Amortization	'	'
Technology/patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	24,300	24,300
Accumulated Amortization	17,118	16,150
Technology/patents [Member] | Stanadyne Corporation [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	24,300	24,300
Accumulated Amortization	17,118	16,150
Customer contracts [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	15,252	15,252
Accumulated Amortization	13,960	12,816
Customer contracts [Member] | Stanadyne Corporation [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	15,252	15,252
Accumulated Amortization	13,960	12,816
Debt issuance costs [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	16,240	14,660
Accumulated Amortization	13,333	10,995
Debt issuance costs [Member] | Stanadyne Corporation [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	13,885	12,305
Accumulated Amortization	11,335	9,192
Other [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	1,851	1,935
Accumulated Amortization	75	75
Other [Member] | Stanadyne Corporation [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	1,851	1,935
Accumulated Amortization	$75	$75

Intangible_and_Other_Assets_Ad

Intangible and Other Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization expense of intangible assets	$704	$704	$2,112	$2,112
Estimated annual amortization expense of intangible assets in 2013	2,816	'	2,816	'
Estimated annual amortization expense of intangible assets in 2014	2,202	'	2,202	'
Estimated annual amortization expense of intangible assets in 2015	1,093	'	1,093	'
Estimated annual amortization expense of intangible assets in 2016	1,072	'	1,072	'
Estimated annual amortization expense of intangible assets in 2017	1,072	'	1,072	'
Estimated annual amortization expense of intangible assets in 2018	1,072	'	1,072	'
Debt issuance costs [Member]	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization expense of intangible assets	844	505	2,338	1,487
Stanadyne Corporation [Member]	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization expense of intangible assets	704	704	2,112	2,112
Stanadyne Corporation [Member] | Debt issuance costs [Member]	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization expense of intangible assets	$779	$440	$2,143	$1,292

Longterm_Debt_and_Financing_Ar2

Long-term Debt and Financing Arrangements - Schedule of Long-term Debt (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Long-term debt	$328,744	$297,684
Less current maturities of long-term debt	218,367	32,416
Long-term debt, excluding current maturities	110,377	265,268
U.S. Revolver [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	22,140	21,090
U.S. term debt, payable to Jefferies Finance LLC through 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	25,000	'
U.S. Convertible Subordinated Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	6,000	'
Senior Subordinated Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	160,000	160,000
Holdings Senior Discount Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	100,000	100,000
SAPL term debt, payable to India banks through 2017 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	4,934	5,982
SAPL Debentures [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	1,057	1,251
SAPL debt, payable to India banks through 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	4,874	4,660
SCC debt, payable to Shanghai-Pudong Development Bank through 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	2,214	2,608
SpA debt, payable to Italian banks through 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	2,525	2,093
Stanadyne Corporation [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	222,744	197,684
Less current maturities of long-term debt	218,367	32,416
Long-term debt, excluding current maturities	4,377	165,268
Stanadyne Corporation [Member] | U.S. Revolver [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	22,140	21,090
Stanadyne Corporation [Member] | U.S. term debt, payable to Jefferies Finance LLC through 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	25,000	'
Stanadyne Corporation [Member] | U.S. Convertible Subordinated Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	0	'
Stanadyne Corporation [Member] | Senior Subordinated Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	160,000	160,000
Stanadyne Corporation [Member] | Holdings Senior Discount Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	'	'
Stanadyne Corporation [Member] | SAPL term debt, payable to India banks through 2017 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	4,934	5,982
Stanadyne Corporation [Member] | SAPL Debentures [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	1,057	1,251
Stanadyne Corporation [Member] | SAPL debt, payable to India banks through 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	4,874	4,660
Stanadyne Corporation [Member] | SCC debt, payable to Shanghai-Pudong Development Bank through 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	2,214	2,608
Stanadyne Corporation [Member] | SpA debt, payable to Italian banks through 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	$2,525	$2,093

Longterm_Debt_and_Financing_Ar3

Long-term Debt and Financing Arrangements - Schedule of Long-term Debt (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2013
U.S. term debt, payable to Jefferies Finance LLC through 2014 [Member]	'
Debt Instrument [Line Items]	'
Interest rate	10.00%
Long-term debt, maturity year	'2014
U.S. Convertible Subordinated Notes [Member]	'
Debt Instrument [Line Items]	'
Interest rate	12.00%
Long-term debt, maturity year	'2018
Senior Subordinated Notes [Member]	'
Debt Instrument [Line Items]	'
Interest rate	10.00%
Long-term debt, maturity year	'2014
Holdings Senior Discount Notes [Member]	'
Debt Instrument [Line Items]	'
Interest rate	12.00%
Long-term debt, maturity year	'2015
SAPL term debt, payable to India banks through 2017 [Member]	'
Debt Instrument [Line Items]	'
Interest rate range, minimum	11.00%
Interest rate range, maximum	12.00%
Long-term debt, maturity year	'2017
SAPL debt, payable to India banks through 2013 [Member]	'
Debt Instrument [Line Items]	'
Interest rate range, minimum	11.00%
Interest rate range, maximum	12.75%
Long-term debt, maturity year	'2013
SCC debt, payable to Shanghai-Pudong Development Bank through 2013 [Member]	'
Debt Instrument [Line Items]	'
Interest rate range, minimum	6.90%
Interest rate range, maximum	7.20%
Long-term debt, maturity year	'2013
SpA debt, payable to Italian banks through 2013 [Member]	'
Debt Instrument [Line Items]	'
Interest rate range, minimum	4.00%
Interest rate range, maximum	6.10%
Long-term debt, maturity year	'2013

Longterm_Debt_and_Financing_Ar4

Long-term Debt and Financing Arrangements - Additional Information (Detail) (USD $)

9 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Aug. 14, 2013

Sep. 30, 2013

Borrowing [Member]

Standby Letters of Credit [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Holdings Senior Discount Notes [Member]

Holdings Senior Discount Notes [Member]

Holdings Senior Discount Notes [Member]

Holdings Senior Discount Notes [Member]

Term Loan Agreement [Member]

U.S. Revolver [Member]

U.S. Revolver [Member]

U.S. Revolver [Member]

U.S. Revolver [Member]

U.S. Revolver [Member]

U.S. Revolver [Member]

Fifth Credit Amendment [Member]

Senior Subordinated Notes [Member]

Senior Subordinated Notes [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation and Jefferies Finance LLC [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

Stanadyne Corporation [Member]

SpA, SAPL, and SCC [Member]

Stanadyne and Wells Fargo Capital Finance, LLC [Member]

Convertible Subordinated Debt [Member]

Convertible Subordinated Debt [Member]

LIBOR margin [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Approximated Fair value and carrying value of notes

'

'

'

'

'

'

$152,000,000

$148,800,000

'

'

$55,000,000

$68,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate original principal amount of term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

'

6,000,000

'

Debt Instrument, Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

Aggregate additional amount of term loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

5,000,000

'

'

Interest on term loan

'

'

'

'

'

'

10.00%

'

'

'

12.00%

'

'

'

10.00%

'

'

'

'

'

'

'

12.00%

'

Line of Credit Facility, Reduced Guaranteed Facility Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

'

Debt instrument due date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Jun-14

'

'

30-Apr-14

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

55,800,000

'

'

'

'

'

'

Pledge percentage of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65.00%

'

'

'

Line of Credit Facility Decrease Increment Amount Required

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility Decrease Notice Period

'10 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Applicable margin percentage minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.25%

'

'

'

'

Applicable margin percentage maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.75%

'

'

'

'

Fixed charge coverage ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.1

'

'

'

'

'

'

Revolving credit threshold where covenant test is required

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

Revolving credit period for proving annual financial information

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'105 days

'

'

'

'

'

'

'

'

Total commitment

328,744,000

297,684,000

'

'

222,744,000

197,684,000

160,000,000

160,000,000

160,000,000

160,000,000

100,000,000

100,000,000

'

'

'

22,140,000

21,090,000

22,140,000

21,090,000

'

'

60,800,000

'

55,800,000

Increased interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25

'

'

Revolving credit, remaining borrowing capacity

'

'

$22,100,000

$3,200,000

'

'

'

'

'

'

'

'

'

'

'

$25,400,000

'

'

'

'

'

'

'

'

Pension_Plans_and_Other_Postre2

Pension Plans and Other Postretirement Health Care and Life Insurance Plans - Components of Net Periodic Pension Expense (Benefit) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Pension plans defined benefit [Member]	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Interest cost	$1,288	$1,405	$3,864	$4,215
Expected return on plan assets	-1,798	-1,601	-5,396	-4,803
Recognized net actuarial loss	923	775	2,770	2,326
Net periodic pension and postretirement benefit	413	579	1,238	1,738
Postretirement health care and life insurance [Member]	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	8	7	23	22
Interest cost	20	26	60	78
Recognized net actuarial loss	-174	-186	-521	-559
Net periodic pension and postretirement benefit	($146)	($153)	($438)	($459)

Pension_Plans_and_Other_Postre3

Pension Plans and Other Postretirement Health Care and Life Insurance Plans - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]	'	'	'	'	'
Contributions to pension plan during period	$1.50	$2.20	$3.20	$4.90	'
Expected minimum required contributions to pension plan	$4.10	'	$4.10	'	$5

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2013	Sep. 30, 2013
		Before consolidation [Member]	After consolidation [Member]
		Building	Building
Property, Plant and Equipment [Line Items]	'	'	'
Number of buildings	'	3	2
Additional accelerated depreciation recognized	$2.90	'	'

Equity_Compensation_Plan_Addit

Equity Compensation Plan - Additional Information (Detail) (2004 Equity Incentive Plan [Member])	9 Months Ended
	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expiration period from grant date	'10 years
Minimum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Vesting period of awards	'1 year
Maximum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Vesting period of awards	'4 years

Equity_Compensation_Plan_Equit

Equity Compensation Plan Equity Compensation Plan - Options (Details) (2004 Equity Incentive Plan [Member], USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012	Jun. 30, 2013		Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'		'	'		'	'		'
Beginning Balance (in shares)	14,778,750		'	14,778,750		'	'		'
Exercised (in shares)	0		'	0		'	'		'
Cancelled (in shares)	-3,375,000		'	-3,375,000		'	'		'
Granted (in shares)	875,000		'	875,000		'	'		'
Ending Balance (in shares)	12,278,750		'	12,278,750		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'		'	'		'	'		'
Weighted Average Exercise Price, Beginning Balance (in dollars per share)	$0.49	[1]	'	$0.49	[1]	'	'		'
Weighted Average Exercise Price, Exercised (in dollars per share)	$0	[1]	'	$0	[1]	'	'		'
Weighted Average Exercise Price, Cancelled (in dollars per share)	$0.47	[1]	'	$0.47	[1]	'	'		'
Weighted Average Exercise Price, Granted (in dollars per share)	$0.47	[1]	'	$0.47	[1]	'	'		'
Weighted Average Exercise Price, Ending Balance (in dollars per share)	$0.49	[1]	'	$0.49	[1]	'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,008,750		'	3,008,750		'	3,008,750		3,008,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$0.47	[1]	'	$0.47	[1]	'	$0.47	[1]	$0.47	[1]
Share-based Compensation Arrangement by Share-based Payment Award, Options to Purchase, Number	875,000		'	875,000		'	'		'
Allocated Share-based Compensation Expense	$0		$0	$0		$0	'		'
Performance Shares [Member]	'		'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'		'	'		'	'		'
Granted (in shares)	875,000		'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'		'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$0.47		'	$0.47		'	'		'
[1]	Represents per share price.

Redeemable_Noncontrolling_Inte1

Redeemable Non-controlling Interest and Financial Instruments - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Noncontrolling Interest [Abstract]	'	'
Non-controlling interest ownership percentage	35.10%	'
Days to exercise put option ownership interests to Stanadyne	'90 days	'
Non-controlling interest at estimated redemption value	$0.50	$0.90

Fair_Value_Measurements_Catego

Fair Value Measurements - Categorizes of Financial Assets and Liabilities Based on Types of Inputs Used in Valuation Techniques for Measuring Fair Value (Detail) (SAPL debenture embedded conversion option [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial liabilities	$1,012	$1,150
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial liabilities	'	'
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial liabilities	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Financial liabilities	$1,012	$1,150

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'	'	'
Fair value assumptions, expected discount yield rate	'	'	15.75%	'
Fair value assumptions, expected volatility rate	'	'	30.00%	'
Fair value assumptions, risk free interest rate	'	'	7.93%	'
Significant Unobservable Inputs Level 3 [Member]	'	'	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'	'	'
Unrealized losses (gains) on Derivatives	$28	($36)	($2)	$690

Segments_Additional_Informatio

Segments - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
	Segment
Segment Reporting [Abstract]	'
Number of reportable segments	1

Commitments_and_Contingencies_1

Commitments and Contingencies - Schedule of Changes in Warranty Liability (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]	'	'	'	'
Warranty liability, beginning of period	$1,272	$726	$893	$774
Warranty expense based on products sold	202	234	1,038	611
Warranty claims paid	-322	-270	-779	-695
Warranty liability, end of period	$1,152	$690	$1,152	$690